Mongodb Inc vs Summit Therapeutics Inc — how do they compare? Mongodb Inc trades at $440.1 (market cap $35.32B), while Summit Therapeutics Inc trades at $15.29 (market cap $12.06B). The key difference: Mongodb Inc is far larger — about 2.9× Summit Therapeutics Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| MDB | SMMT | |
|---|---|---|
Market Cap | $35.32B | $12.06B |
Sector | Technology | Health |
52-Week High | $440.25 | $26.98 |
52-Week Low | $204.37 | $12.55 |
Enterprise Value | $32.93B | $11.39B |
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $416.67, up 4.48% in the last session, with a bullish technical setup per moving averages and ADX. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent earnings beats and strong analyst sentiment, with 82% buy ratings, support optimism. The stock is near its pivot point of $412, with resistance at $428.
Outlook: MDB's growth trajectory and AI-driven demand present upside, but profitability concerns and high valuation multiples (P/S 13.73) pose risks. Investors should weigh revenue momentum against persistent losses and competitive pressures in the database software market.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Trailing returns across standard periods
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →